» Articles » PMID: 34349004

Plasma NfL Levels and Longitudinal Change Rates in and -associated Diseases: from Tailored References to Clinical Applications

Abstract

Objective: Neurofilament light chain (NfL) is a promising biomarker in genetic frontotemporal dementia (FTD) and amyotrophic lateral sclerosis (ALS). We evaluated plasma neurofilament light chain (pNfL) levels in controls, and their longitudinal trajectories in and cohorts from presymptomatic to clinical stages.

Methods: We analysed pNfL using Single Molecule Array (SiMoA) in 668 samples (352 baseline and 316 follow-up) of and patients, presymptomatic carriers (PS) and controls aged between 21 and 83. They were longitudinally evaluated over a period of >2 years, during which four PS became prodromal/symptomatic. Associations between pNfL and clinical-genetic variables, and longitudinal NfL changes, were investigated using generalised and linear mixed-effects models. Optimal cut-offs were determined using the Youden Index.

Results: pNfL levels increased with age in controls, from ~5 to~18 pg/mL (p<0.0001), progressing over time (mean annualised rate of change (ARC): +3.9%/year, p<0.0001). Patients displayed higher levels and greater longitudinal progression (ARC: +26.7%, p<0.0001), with gene-specific trajectories. patients had higher levels than (86.21 vs 39.49 pg/mL, p=0.014), and greater progression rates (ARC:+29.3% vs +24.7%; p=0.016). In patients, levels were associated with the phenotype (ALS: 71.76 pg/mL, FTD: 37.16, psychiatric: 15.3; p=0.003) and remarkably lower in slowly progressive patients (24.11, ARC: +2.5%; p=0.05). Mean ARC was +3.2% in PS and +7.3% in prodromal carriers. We proposed gene-specific cut-offs differentiating patients from controls by decades.

Conclusions: This study highlights the importance of gene-specific and age-specific references for clinical and therapeutic trials in genetic FTD/ALS. It supports the usefulness of repeating pNfL measurements and considering ARC as a prognostic marker of disease progression.

Trial Registration Numbers: NCT02590276 and NCT04014673.

Citing Articles

Comprehensive cross-sectional and longitudinal comparisons of plasma glial fibrillary acidic protein and neurofilament light across FTD spectrum disorders.

Sheth U, Oijerstedt L, Heckman M, White L, Heuer H, Lario Lago A Mol Neurodegener. 2025; 20(1):30.

PMID: 40075459 PMC: 11905702. DOI: 10.1186/s13024-025-00821-4.


Plasma Biomarkers in the Distinction of Alzheimer's Disease and Frontotemporal Dementia.

Gomez-Tortosa E, Aguero-Rabes P, Ruiz-Gonzalez A, Wagner-Reguero S, Tellez R, Mahillo I Int J Mol Sci. 2025; 26(3).

PMID: 39940998 PMC: 11818795. DOI: 10.3390/ijms26031231.


Clinical features and progress in diagnosis and treatment of amyotrophic lateral sclerosis.

Yuan D, Jiang S, Xu R Ann Med. 2024; 56(1):2399962.

PMID: 39624969 PMC: 11616751. DOI: 10.1080/07853890.2024.2399962.


Blood-Based Biomarkers in Frontotemporal Dementia: A Narrative Review.

Liampas I, Kyriakoulopoulou P, Karakoida V, Kavvoura P, Sgantzos M, Bogdanos D Int J Mol Sci. 2024; 25(21).

PMID: 39519389 PMC: 11546606. DOI: 10.3390/ijms252111838.


The Miami Framework for ALS and related neurodegenerative disorders: an integrated view of phenotype and biology.

Benatar M, Wuu J, Huey E, McMillan C, Petersen R, Postuma R Nat Rev Neurol. 2024; 20(6):364-376.

PMID: 38769202 PMC: 11216694. DOI: 10.1038/s41582-024-00961-z.


References
1.
Steinacker P, Anderl-Straub S, Diehl-Schmid J, Semler E, Uttner I, von Arnim C . Serum neurofilament light chain in behavioral variant frontotemporal dementia. Neurology. 2018; 91(15):e1390-e1401. DOI: 10.1212/WNL.0000000000006318. View

2.
Sudre C, Bocchetta M, Heller C, Convery R, Neason M, Moore K . White matter hyperintensities in progranulin-associated frontotemporal dementia: A longitudinal GENFI study. Neuroimage Clin. 2019; 24:102077. PMC: 6911860. DOI: 10.1016/j.nicl.2019.102077. View

3.
Mattsson N, Cullen N, Andreasson U, Zetterberg H, Blennow K . Association Between Longitudinal Plasma Neurofilament Light and Neurodegeneration in Patients With Alzheimer Disease. JAMA Neurol. 2019; 76(7):791-799. PMC: 6583067. DOI: 10.1001/jamaneurol.2019.0765. View

4.
Millecamps S, Boillee S, Le Ber I, Seilhean D, Teyssou E, Giraudeau M . Phenotype difference between ALS patients with expanded repeats in C9ORF72 and patients with mutations in other ALS-related genes. J Med Genet. 2012; 49(4):258-63. DOI: 10.1136/jmedgenet-2011-100699. View

5.
Baker M, Mackenzie I, Pickering-Brown S, Gass J, Rademakers R, Lindholm C . Mutations in progranulin cause tau-negative frontotemporal dementia linked to chromosome 17. Nature. 2006; 442(7105):916-9. DOI: 10.1038/nature05016. View